Robert Duggan via YouTube

Phar­ma­cyclics bil­lion­aire Bob Dug­gan takes the helm of an­oth­er biotech — and he faces an even big­ger up­hill climb this time

Five years af­ter turn­ing his stake in Phar­ma­cyclics in­to a per­son­al for­tune worth more than a bil­lion dol­lars, Bob Dug­gan is back at the helm of a biotech. He’s once again fight­ing the odds in mak­ing a biotech a suc­cess — but this time in­stead of on­col­o­gy, where he made biotech his­to­ry with Im­bru­vi­ca, he’s tak­en the reins on a late-stage pro­gram for an an­tibi­ot­ic.

And noth­ing is quite as chilly right now as an­tibi­otics.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.